食欲素受体拮抗剂类抗失眠药物的研究进展  

Research Progress of Anti-Insomnia Drugs of Orexin Receptor Antagonist

作　　者：于景娴[1] 池里群[1] YU Jing-xian;CHI Li-qun(Department of Pharmacy,Haidian Maternal and Child Health Hospital,Beijing 100080,China)

机构地区：[1]北京市海淀区妇幼保健院药剂科,北京100080

出　　处：《中国合理用药探索》2024年第2期20-25,共6页Chinese Journal of Rational Drug Use

摘　　要：随着现代社会生活节奏的加快,失眠的患病率逐渐增加,长期失眠会严重影响个人的工作和生活。目前临床常用的改善失眠症状的药物主要为镇静催眠药。作为新一代抗失眠药物,食欲素受体拮抗剂可以增加睡眠各阶段的持续时间、减弱觉醒信号从而抑制清醒状态而非诱导镇静,从而可以有效避免传统镇静催眠药物的一些缺点。本研究对食欲素受体拮抗剂中3个明星药物suvorexant、lemborexant、daridorexant的有效性和安全性进展进行综述,以期为治疗失眠提供参考。With the acceleration of modern life,the prevalence of insomnia is gradually increasing,which can significantly impact individuals'work and life.Currently,the primary medications used to alleviate insomnia symptoms in clinical practice are sedative-hypnotic drugs.As a new generation of anti-insomnia drugs,orexin receptor antagonists can increase the duration of each stage of sleep,weaken the arousal signal,thus inhibiting wakefulness rather than inducing sedation,and effectively avoiding some disadvantages of traditional sedative-hypnotic drugs.This article provides a review of the research progress of the efficacy and safety of three prominent drugs,suvorexant,lemborexant,and daridorexant,as orexin receptor antagonists,aiming to provide reference for the treatment of insomnia.

关 键 词：食欲素受体拮抗剂 抗失眠药物 有效性 安全性 综述 

分 类 号：R971.3[医药卫生—药品]